Synairgen (LON:SNG) Trading Up 5.2% – Should You Buy?

Synairgen plc (LON:SNG) shares shot up 5.2% during mid-day trading on Wednesday . The stock traded as high as GBX 1.05 ($0.01) and last traded at GBX 1 ($0.01). 2,581,250 shares traded hands during trading, an increase of 68% from the average session volume of 1,532,359 shares. The stock had previously closed at GBX 0.95 ($0.01).

Synairgen Price Performance

The firm has a 50-day moving average of GBX 1.69 and a 200 day moving average of GBX 3.05. The stock has a market capitalization of £10.55 million, a price-to-earnings ratio of -0.65 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).